Scil Technology Enrols First Patient in Phase II Sinus Lift Study

Scil Technology, a biopharmaceutical company focused on the development of dental and orthopaedic tissue regeneration products, today announced that it has enrolled the first patient in a Phase II Clinical Trial of its novel bone augmentation product, MD05, developed for bone regeneration in dental implantology and also in bone defects in severe periondontal disease.

Source: Scil Technology